<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9500169</journal-id>
<journal-id journal-id-type="pubmed-jr-id">20475</journal-id>
<journal-id journal-id-type="nlm-ta">Neurobiol Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurobiol. Dis.</journal-id>
<journal-title-group>
<journal-title>Neurobiology of disease</journal-title>
</journal-title-group>
<issn pub-type="ppub">0969-9961</issn>
<issn pub-type="epub">1095-953X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30928642</article-id>
<article-id pub-id-type="pmc">6760869</article-id>
<article-id pub-id-type="doi">10.1016/j.nbd.2019.03.029</article-id>
<article-id pub-id-type="manuscript">NIHMS1538877</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>NitroSynapsin for the treatment of neurological manifestations of Tuberous Sclerosis Complex in a rodent model</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Okamoto</surname>
<given-names>Shu-ichi</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="author-notes" rid="FN2">†</xref>
<xref ref-type="author-notes" rid="FN5">§</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Prikhodko</surname>
<given-names>Olga</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="author-notes" rid="FN5">§</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pina-Crespo</surname>
<given-names>Juan</given-names>
</name>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Adame</surname>
<given-names>Anthony</given-names>
</name>
<xref ref-type="aff" rid="A4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McKercher</surname>
<given-names>Scott R.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A5">e</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brill</surname>
<given-names>Laurence M.</given-names>
</name>
<xref ref-type="aff" rid="A3">c</xref>
<xref ref-type="author-notes" rid="FN4">¶</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nakanishi</surname>
<given-names>Nobuki</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oh</surname>
<given-names>Chang-ki</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A5">e</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nakamura</surname>
<given-names>Tomohiro</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A5">e</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Masliah</surname>
<given-names>Eliezer</given-names>
</name>
<xref ref-type="aff" rid="A4">d</xref>
<xref ref-type="author-notes" rid="FN3">‡</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lipton</surname>
<given-names>Stuart A.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A4">d</xref>
<xref ref-type="aff" rid="A5">e</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>Scintillon Institute, San Diego, CA 92121, USA.</aff>
<aff id="A2"><label>b</label>Biomedical Sciences Graduate Program, University of California San Diego, School of Medicine, La Jolla, CA 92093.</aff>
<aff id="A3"><label>c</label>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.</aff>
<aff id="A4"><label>d</label>Department of Neurosciences, University of California San Diego, School of Medicine, La Jolla, CA 92093, USA.</aff>
<aff id="A5"><label>e</label>Neuroscience Translational Center, and Departments of Molecular Medicine and Neuroscience, The Scripps Research Institute, La Jolla, CA 92093, USA.</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Correspondence should be addressed to: <email>slipton@scripps.edu</email></corresp>
<fn fn-type="con" id="FN1">
<p id="P1">Author Contributions</p>
<p id="P2">S-i.O., J.P.-C., L.M.B., S.A.L. designed experiments; S-i.O., O.P., J.P.-C., A.A., L.M.B. performed experiments; O.P., J.P.-C., S-i.O., L.M.B., E.M., S.R.M., N.N, S.A.L. analyzed data; O.P., J.P.-C., S-i.O., S.R.M., N.N., S.A.L. wrote the manuscript.</p>
</fn>
<fn fn-type="present-address" id="FN2">
<label>†</label>
<p id="P3">Present address: Takeda Pharmaceutical Company, Ltd., Tokyo, Japan.</p>
</fn>
<fn fn-type="present-address" id="FN3">
<label>‡</label>
<p id="P4">Present address: National Institute on Aging/NIH, Bethesda, MD 20892, USA.</p>
</fn>
<fn fn-type="present-address" id="FN4">
<label>¶</label>
<p id="P5">Present address: Intertek Pharmaceutical Services, Bioanalytical and Proteomic LCMS, San Diego, CA 92121, USA.</p>
</fn>
<fn fn-type="equal" id="FN5">
<label>§</label>
<p id="P6">These authors contributed equally to the work.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>5</day>
<month>9</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>27</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>7</month>
<year>2020</year>
</pub-date>
<volume>127</volume>
<fpage>390</fpage>
<lpage>397</lpage>
<!--elocation-id from pubmed: 10.1016/j.nbd.2019.03.029-->
<abstract id="ABS1">
<p id="P7">Tuberous sclerosis (TSC) is an autosomal dominant disorder caused by heterozygous mutations in the TSC1 or TSC2 gene. TSC is often associated with neurological, cognitive, and behavioral deficits. TSC patients also express co-morbidity with anxiety and mood disorders. The mechanism of pathogenesis in TSC is not entirely clear, but TSC-related neurological symptoms are accompanied by excessive glutamatergic activity and altered synaptic spine structures. To address whether extrasynaptic (e)NMDA-type glutamate receptor (NMDAR) antagonists, as opposed to antagonists that block physiological phasic synaptic activity, can ameliorate the synaptic and behavioral features of this disease, we utilized the <italic>Tsc2</italic><sup>+/−</sup> mouse model of TSC to measure biochemical, electrophysiological, histological, and behavioral parameters in the mice. We found that antagonists that preferentially block tonic activity as found at eNMDARs, particularly the newer drug NitroSynapsin, provide biological and statistically significant improvement in <italic>Tsc2</italic><sup>+/−</sup> phenotypes. Accompanying this improvement was correction of activity in the p38 MAPK-TSC-Rheb-mTORC1-S6K1 pathway. Deficits in hippocampal long-term potentiation (LTP), histological loss of synapses, and behavioral fear conditioning in <italic>Tsc2</italic><sup>+/−</sup> mice were all improved after treatment with NitroSynapsin. Taken together, these results suggest that amelioration of excessive excitation, by limiting aberrant eNMDAR activity, may represent a novel treatment approach for TSC.</p>
</abstract>
<kwd-group>
<kwd>Tuberous Sclerosis</kwd>
<kwd>NitroSynapsin</kwd>
<kwd>extrasynaptic NMDA receptor</kwd>
<kwd>E/I imbalance</kwd>
<kwd>hippocampal long-term potentiation</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>